Advanced Search

The story appears on

Page A3

April 12, 2021

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home 禄 Nation

New Sinopharm vaccine gets nod for clinical trials

Source: Agencies | 00:00 UTC+8 April 12, 2021 | Print Edition

A NEW COVID-19 vaccine developed by China’s Sinopharm has been approved for clinical trials.

The new recombinant COVID-19 vaccine, developed by the National Vaccine & Serum Institute, a R&D center of Sinopharm’s bioscience subsidiary the China National Biotec Group, got approval from the National Medical Products Administration on Friday, the CNBG said on its official Weibo account on Saturday.

The vaccine is based on the structural features of the receptor binding domain on the virus’ spike protein (S-protein). It uses genetic engineering to grow harmless copies of the virus S-protein to induce neutralizing antibodies.

The company said that recombinant vaccine technology is mature and suitable for large-scale production. The production does not require facilities with high biosafety levels since the process does not involve live viruses.

The recombinant vaccine is the company’s third COVID-19 vaccine. More than ten vaccine candidates led by Chinese scientists have entered different stages of clinical trials.

Four vaccines, two from Sinopharm CNBG, one from Sinovac Biotech and one from CanSino Biologics, have been cleared for use among the general public.

A fifth vaccine from the Institute of Microbiology of the Chinese Academy of Sciences, which is also based on protein, has gained the green light for limited emergency use.

Nation
锘

 

Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

娌叕缃戝畨澶 31010602000204鍙

Email this to your friend


锘